Cantel Medical Corp. (NYSE:CMD) Q4 2020 Earnings Conference Call - Final Transcript
Sep 17, 2020 • 08:30 am ET
to streamline our processes to improve profit and accelerate growth.
In parallel, we have continued to execute on our commercial excellence training and deployment across Europe at an accelerated pace. We expect this to translate into strong second half '21 commercial performance in EMEA.
Finally, we continue to make excellent progress on the integration of Hu-Friedy into our Dental business. As mentioned earlier, the value proposition of infection prevention in the dentist office is unprecedented, and the addition of Hu-Friedy enhances this unique offering. There is more to come over the next few months. But in short, a new scaler, increased instrument management system setups, Greenlight 2.0 launch, and an overall enhanced focus on education add to our confidence on the future for this business.
Despite the impact of COVID on our end markets, we have continued to focus and execute on our key strategic priorities while carefully managing our expenses and key resources.
I want to take this time to thank our global teams for their daily efforts to produce essential products and deliver critical services to our customers and stakeholders during these extraordinary times.
With that, we are now ready for questions.